Aconex Limited (ASX:ACX), a global leader of digital innovation in construction, has been selected by the judges as a finalist in the Technology Supplier of the Year category of the 2017 Construction News Specialists Awards, the only national awards that recognise the best specialist contractors from across the whole of the UK.

Peak Asset Management's latest Corporate Opportunity, Lifespot Health, is now live. Bids close Wednesday 10am given exceptional demand. Peak's last three deals are up at least 100% since listing as at close on Friday, 2 December 2016.

Cancer is the great scourge of our age. This year, 1.7 million Americans will find out they have the disease and some 600,000 will die from it. In total, approximately 40 percent of the population can expect to be diagnosed with cancer during their lifetime. The name "cancer" is derived from the Greek word for crab and may have been bestowed to indicate the tenacity of the disorder. Cancer tends to persist with the same relentlessness as the claws of a crab cling to a victim.

Social media has become a dominating force in the marketing world over the past decade. Businesses use this form of marketing to attract prospective customers, increase sales, and build relationships with their target markets. According to an article by Neil Patel (http://nnw.fm/6FCdl), research has found that social media drives over 30% of overall referral traffic on the Internet.

A legal dispute with the European Patent Office over the European patent for its lead product candidate surprisingly presents a strong buying opportunity for clinical stage biopharmaceutical company Alder Biopharmaceuticals, Inc. (NASDAQ:ALDR), according to an analysis report (http://nnw.fm/8j0TO) released by Aegis Capital Corp on November 23. As such, Aegis analysts reiterated a 'Buy' rating for the company and proposed a higher stock price target of $41, compared to the $25.28 stock price at the time the report was issued.

Before the opening bell, Net Element, Inc. (NASDAQ:NETE), through subsidiary PayOnline, announced a new partnership with Flight.az, a subsidiary of Delta Group, Ltd that's recognized as a leading online travel agency (OTA) in Azerbaijan. Under the terms of this contract, PayOnline integrated secure online, mobile payments acceptance functionality, as well as its proprietary 'Avia2Split' technology, into the OTA's existing booking platform, giving Flight.az the tools to better serve its target market of roughly 10 million people living in Southwestern Asia.

Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharma company that focuses on the development of innovative treatments for chronic kidney disease-related anemia, is maintaining its 'Buy' rating, with a recommended stock price target of $18 compared to the current $8.90, according to an Aegis Capital Corp. report (http://nnw.fm/F4ezY) released on November 15. The rating and suggested stock price were based on discounted cash flow analysis and the estimated 2016-2022 EBITDA, with a discount rate of eight percent, the report said.

Fortress Biotech, Inc. (NASDAQ:FBIO) is not putting all its eggs in one basket. This is a biopharmaceutical company with multiple revenue streams and a profuse product portfolio so diversified that Harry Markowitz, the father of modern portfolio theory, might tip his hat to the way the company has sought to mitigate developmental risks. Fortress' diverse product pipeline also gives it multiple shots at hitting its financial goals, increased by the symbiotic relationship between development areas. The research platforms are structured so that success in one area is likely to add impetus to another.

Topbetta Holdings Ltd (ASX:TBH) is pleased to announce that corporate bookmaker Ladbrokes.com.au, the Australian subsidiary for the UK parent and world wagering leader Ladbrokes Coral Group plc., has signed on as the first wagering operator to commit to using The Global Tote.

Zogenix, Inc (NASDAQ:ZGNX) is a clinical stage pharmaceutical company committed to the development and commercialization of therapies for central nervous system disorders that address specific clinical needs for people living with orphan diseases. The company's lead product candidate, ZX008, is currently being evaluated for the treatment of one such disease - Dravet Syndrome.